RxDoctor Payments Data

Brittany Root

Primary Care · Rock Hill, SCNPI 1639878895

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.6% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations.

$3,319in general payments, 2019–2025

Across 169 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$795
  • GSK$430
  • Jazz Pharmaceuticals Inc.$390
  • Regeneron Healthcare Solutions, Inc.$230
  • Insmed, Inc.$194
  • Mylan Specialty L.p.$190
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$1505%
  • Food & beverage$3,00891%
  • Education$1615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,319 in reported general payments places this provider in the 85th percentile of 115 primary care providers in South Carolina.

See all primary care providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter215$267,638
Breztri AerosphereBudesonide/Glycopyr/Formoterol140$186,452
Breo ElliptaFluticasone/Vilanterol97$73,074
Spiriva RespimatTiotropium Bromide61$68,670
Stiolto RespimatTiotropium Br/Olodaterol Hcl55$52,409
SymbicortBudesonide/Formoterol Fumarate70$38,360
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$30,726
Fluticasone-SalmeterolFluticasone Propion/Salmeterol85$26,967
Incruse ElliptaUmeclidinium Bromide29$26,055
Albuterol Sulfate HfaAlbuterol Sulfate518$20,244
Combivent RespimatIpratropium/Albuterol Sulfate20$18,452
Arnuity ElliptaFluticasone Furoate32$15,955
DuleraMometasone/Formoterol21$14,711
Wixela InhubFluticasone Propion/Salmeterol46$10,845
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$7,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$430$413,448403 claims
AstraZenecaBreztri Aerosphere, Symbicort$795$224,812210 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$70$139,531136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 115 primary care providers in South Carolina.

Other primary care in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →